Zobrazeno 1 - 10 of 2 805 pro vyhledávání: '"Davies BR"'
1
Akademický článek
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Autor: Staniszewska AD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Pilger D; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gill SJ; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Jamal K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Bohin N; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Guzzetti S; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gordon J; Oncology R&D, AstraZeneca, Boston, Massachusetts., Hamm G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Mundin G; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Pike A; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McWilliams L; Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Maglennon G; Pathology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Rose J; Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Hawthorne G; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Cortes Gonzalez M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Halldin C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Johnström P; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, Oncology R&D, Stockholm, Sweden., Schou M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, Oncology R&D, Stockholm, Sweden., Critchlow SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Fawell S; Oncology R&D, AstraZeneca, Boston, Massachusetts., Johannes JW; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts., Leo E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Davies BR; Projects Group, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Cosulich S; Projects Group, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Sarkaria JN; Mayo Clinic, Rochester, Minnesota., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hamerlik P; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 01; Vol. 30 (7), pp. 1338-1351.
Zobrazit plný text záznamu
2
Akademický článek
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Autor: Pearson ADJ; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium. Electronic address: andy1pearson@btinternet.com., Federico S; St Jude Children's Research Hospital, Memphis, TN, USA., Gatz SA; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Ortiz M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Scobie N; Zoe4Life, Sullens, Switzerland., Gounaris I; Merck Serono Ltd (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, UK., Weiner SL; Children's Cancer Cause, Washington, DC, USA., Weigel B; University of Minnesota, Minneapolis, MN, USA., Unger TJ; Repare Therapeutics, Cambridge, MA, USA., Stewart E; St Jude Children's Research Hospital, Memphis, TN, USA., Smith M; National Cancer Institute, Bethesda, MD, USA., Slotkin EK; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reaman G; US Food and Drug Administration, Silver Springs, MD, USA., Pappo A; St Jude Children's Research Hospital, Memphis, TN, USA., Nysom K; Righospitalet, Copenhagen, Denmark., Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency (EMA), Amsterdam, the Netherlands; Federal Agency for Medicines and Health Products, Brussels, Belgium., McDonough J; The Andrew McDonough B+ Foundation, Wilmington, DE, USA., Marshall LV; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK., Ludwinski D; Solving Kids' Cancer, New York, NY, USA., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Kool M; Hopp Children's Cancer Center, Heidelberg, Germany., Horner TJ; GSK, Collegeville, PA, USA., Henssen A; Charité Berlin, Berlin, Germany., Heenen D; KickCancer, Brussels, Belgium., Hawkins DS; Seattle Children's Hospital, Seattle, WA, USA; Children's Oncology Group, Seattle, WA, USA., Gore L; Children's Hospital Colorado, Aurora, CO, USA; University of Colorado School of Medicine, Aurora, CO, USA., Bender JG; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Galluzzo S; Italian Medicine Agency (AIFA), Rome, Italy., Fox E; St Jude Children's Research Hospital, Memphis, TN, USA., de Rojas T; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium., Davies BR; AstraZeneca, Cambridge, UK., Chakrabarti J; Pfizer, Tadworth, UK., Carmichael J; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK., Bradford D; US Food and Drug Administration, Silver Springs, MD, USA., Blanc P; Imagine for Margo, Paris, France., Bernardi R; Genentech, a Member of the Roche Group, South San Francisco, CA, USA., Benchetrit S; National Agency for the Safety of Medicine and Health Products, Paris, France., Akindele K; The Dorcas Foundation, Lagos, Nigeria., Vassal G; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium; Gustave Roussy Cancer Centre, Paris, France.
Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 190, pp. 112950. Date of Electronic Publication: 2023 Jun 21.
Zobrazit plný text záznamu
3
Akademický článek
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Autor: Zelceski A; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Francica P; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; Departement of Biomedical Research (DBMR), Cancer Therapy Resistance Cluster, University of Bern, 3012 Bern, Switzerland., Lingg L; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; Departement of Biomedical Research (DBMR), Cancer Therapy Resistance Cluster, University of Bern, 3012 Bern, Switzerland., Mutlu M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland., Stok C; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands., Liptay M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland., Alexander J; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Baxter JS; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Brough R; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Gulati A; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Haider S; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Raghunandan M; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Song F; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Sridhar S; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Forment JV; Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, UK., Davies BR; Oncology R&D, AstraZeneca, Cambridge, UK., van Vugt MATM; Oncology R&D, AstraZeneca, Cambridge, UK., Krastev DB; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Pettitt SJ; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Electronic address: Stephen.pettitt@icr.ac.uk., Tutt ANJ; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Electronic address: Andrew.tutt@icr.ac.uk., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; Departement of Biomedical Research (DBMR), Cancer Therapy Resistance Cluster, University of Bern, 3012 Bern, Switzerland; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Bern Center for Precision Medicine, University of Bern, 3012 Bern, Switzerland. Electronic address: sven.rottenberg@vetsuisse.unibe.ch., Lord CJ; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Electronic address: Chris.lord@icr.ac.uk.
Publikováno v: Cell reports [Cell Rep] 2023 May 30; Vol. 42 (5), pp. 112484. Date of Electronic Publication: 2023 May 09.
Zobrazit plný text záznamu
4
Akademický článek
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Autor: Dunn S; Wellcome Sanger Institute, Cambridge, UK.; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Eberlein C; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Yu J; Wellcome Sanger Institute, Cambridge, UK.; Molecular Biology of Metabolism Lab, The Francis Crick Institute, London, UK., Gris-Oliver A; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Ong SH; Wellcome Sanger Institute, Cambridge, UK., Yelland U; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Cureton N; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Staniszewska A; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., McEwen R; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Fox M; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Pilling J; Discovery Sciences, AstraZeneca, Cambridge, UK., Hopcroft P; Discovery Sciences, AstraZeneca, Cambridge, UK., Coker EA; Wellcome Sanger Institute, Cambridge, UK., Jaaks P; Wellcome Sanger Institute, Cambridge, UK., Garnett MJ; Wellcome Sanger Institute, Cambridge, UK., Isherwood B; Discovery Sciences, AstraZeneca, Cambridge, UK., Serra V; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Davies BR; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Barry ST; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK. Simon.T.Barry@astrazeneca.com., Lynch JT; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Yusa K; Wellcome Sanger Institute, Cambridge, UK. k.yusa@infront.kyoto-u.ac.jp.; Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan. k.yusa@infront.kyoto-u.ac.jp.
Publikováno v: Oncogene [Oncogene] 2022 Nov; Vol. 41 (46), pp. 5046-5060. Date of Electronic Publication: 2022 Oct 14.
Zobrazit plný text záznamu
5
Akademický článek
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8 H -purin-8-one Inhibitors of DNA-PK.
Autor: Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ting AKT; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Finlay MRV; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Harmer AR; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Adeyemi OB; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Nordell P; Biopharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden., Cronin AS; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cadogan EB; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Davies BR; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2022 Jul 07; Vol. 13 (8), pp. 1295-1301. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).
Zobrazit plný text záznamu
7
Akademický článek
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Autor: Nakamura K; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Karmokar A; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Farrington PM; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., James NH; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Ramos-Montoya A; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Bickerton SJ; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Hughes GD; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Illidge TM; Targeted Therapy Group, Division of Cancer Sciences, University of Manchester, Christie Hospital, Manchester NIHR Biomedical Research Centre, Manchester, United Kingdom., Cadogan EB; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Davies BR; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Dovedi SJ; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. simon.dovedi@astrazeneca.com., Valge-Archer V; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Aug 01; Vol. 27 (15), pp. 4353-4366. Date of Electronic Publication: 2021 May 19.
Zobrazit plný text záznamu
8
Akademický článek
Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
Autor: Jiang Y; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Martin J; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Alkadhimi M; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Shigemori K; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Kinchesh P; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Gilchrist S; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Kersemans V; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Smart S; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Thompson JM; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Hill MA; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., O'Connor MJ; Early Oncology, AstraZeneca, Cambridge, UK., Davies BR; Early Oncology, AstraZeneca, Cambridge, UK., Ryan AJ; CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. anderson.ryan@oncology.ox.ac.uk.
Publikováno v: British journal of cancer [Br J Cancer] 2021 May; Vol. 124 (11), pp. 1809-1819. Date of Electronic Publication: 2021 Mar 19.
Zobrazit plný text záznamu
9
Akademický článek
Per-recruit analysis and proposed sustainable harvest strategy for rednose labeo Labeo rosae and Mosambique tilapia Oreochromis mossambicus in Flag Boshielo Dam, Olifants River, South Africa.
Autor: Marr, SM1,2 (AUTHOR), Hlungwani, HA1,3 (AUTHOR), Weyl, OLF2 (AUTHOR), Sara, JR1 (AUTHOR) joseph.sara@ul.ac.za
Publikováno v: African Journal of Aquatic Science. Oct2024, p1-14. 14p.
Zobrazit plný text záznamu
10
Akademický článek
Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Autor: Patterson CM; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Balachander SB; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Grant I; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK., Pop-Damkov P; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Kelly B; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., McCoull W; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Parker J; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Giannis M; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., Hill KJ; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK., Gibbons FD; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Hennessy EJ; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Kemmitt P; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Harmer AR; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Gales S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Purbrick S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Redmond S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, 02451, USA., Skinner M; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Graham L; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Secrist JP; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Schuller AG; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Wen S; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Adam A; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Reimer C; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Cidado J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Wild M; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Gangl E; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Fawell SE; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Saeh J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Davies BR; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Owen DJ; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., Ashford MB; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. Marianne.Ashford@astrazeneca.com.
Publikováno v: Communications biology [Commun Biol] 2021 Jan 25; Vol. 4 (1), pp. 112. Date of Electronic Publication: 2021 Jan 25.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje